precise immune cell targeting

targeting technology

First in class iL2r agonist

CT101 cancer immunotherapy

courier technology
Dedidcated to cancer therapy

Our team

John Westwick, PhD

CEO, CoFounder, Board

Alexander Krupnick, PhD

CSO, CoFounder, Board

Sarah Hein, PhD

CoFounder, VP Operations

Eric Lazear, PhD

CoFounder, VP Research
our team
Stay in touch

CONTACT US

Thank you! Your message has been received.
Oops! Something went wrong while submitting the form.